Frederick Raal to Ezetimibe
This is a "connection" page, showing publications Frederick Raal has written about Ezetimibe.
Connection Strength
3,138
-
Ezetimibe in the management of homozygous familial hypercholesterolaemia. J Clin Lipidol. 2025 Mar-Apr; 19(2):320-326.
Score: 0,952
-
The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study. Cardiovasc J Afr. 2020 Sep/Oct; 31(5):245-251.
Score: 0,712
-
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arterioscler Thromb Vasc Biol. 2024 May; 44(5):1156-1164.
Score: 0,228
-
Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2023 11 30; 30(17):1874-1880.
Score: 0,223
-
Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study. Circulation. 2020 06 02; 141(22):1829-1831.
Score: 0,175
-
PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility. Endocr Metab Immune Disord Drug Targets. 2020; 20(6):840-854.
Score: 0,170
-
Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis. 2018 10; 277:483-492.
Score: 0,156
-
Effect of Alirocumab on Lipoprotein(a) Over =1.5 Years (from the Phase 3 ODYSSEY Program). Am J Cardiol. 2017 Jan 01; 119(1):40-46.
Score: 0,136
-
Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012 Nov 13; 126(20):2408-17.
Score: 0,103
-
A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. Cardiovasc J Afr. 2007 Sep-Oct; 18(5):325-9.
Score: 0,072
-
Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2024 Dec 14; 404(10470):2462-2475.
Score: 0,060
-
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. Lancet Diabetes Endocrinol. 2022 10; 10(10):732-740.
Score: 0,051
-
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Arterioscler Thromb Vasc Biol. 2018 03; 38(3):592-598.
Score: 0,037
-
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21; 38(32):2459-2472.
Score: 0,036
-
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J. 2014 Sep 01; 35(33):2249-59.
Score: 0,028